Table 2. Overall network meta-analysis results of progression free survival and overall survival.
| Lenalidomide | 1.122 (0.597 to 2.109) | 1.112 (0.633 to 1.952) | 0.954 (0.641 to 1.418) |
| 0.741 (0.494 to 1.111) | Ofatumumab | 0.991 (0.526 to 1.867) | 0.851 (0.521 to 1.391) |
| 0.713 (0.486 to 1.046) | 0.962 (0.668 to 1.386) | Rituximab | 0.862 (0.584 to 1.280) |
| 0.370 (0.275 to 0.499) | 0.501 (0.381 to 0.662) | 0.522 (0.412 to 0.660) | Observation |
The bottom half shows the results of network meta-analyses of progression free survival (hazard ratio and 95% confidence interval);
The top half shows the results of overall survival (hazard ratio and 95% confidence interval). Boldface letter indicates statistical significance.